Clinical trials: Stem Cells
Optic Neuropathy
Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells
A single arm, single center trial to assess the safety and efficacy of restoring function in damaged optic nerves using autologous purified populations of bone-marrow derived stem cells (BM-SCs) through a 24 month follow up…
- Trial name
- NCT02638714
- Testing
- Stem Cells
- Where
- Jordan
- Volunteers
- 100 people
- Sponsor
- Stem Cells Arabia
Interstitial Lung Diseases
Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases
Interstitial lung diseases (ILD) are a group of diseases affecting the lung interstitium. The lung scarring that occurs in ILD is often irreversible with only mitigating therapy available so far.
- Trial name
- NCT02796781
- Testing
- Lung stem cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai East Hospital
Breast Cancer
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells.
- Trial name
- NCT00002509
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Sponsor
- Temple University
Lymphoma, Neutropenia
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.
- Trial name
- NCT00005787
- Testing
- epoetin alfa, filgrastim, recombinant flt3 ligand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for…
- Trial name
- NCT04264806
- Testing
- Azacitidine, Cusatuzumab
- Where
- 73 sites in Australia, Brazil and 9 more
- Sponsor
- Janssen Research & Development, LLC
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Acute Myeloid Leukemia, Minimal Residual Disease Negativity
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
This phase II trial studies how well autologous stem cell transplant works in treating patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute myeloid leukemia.
- Trial name
- NCT03515707
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Poor Graft Function
Decitabine for Poor Graft Function Post Allo-HSCT
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
- Trial name
- NCT05907499
- Testing
- Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist
- Where
- China
- Volunteers
- 76 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Pened Chest Surgery for Programmes Coronary Bypass
Mesenchymal Stem Cells: Alterations in Genome
The aim is to study small genetic alterations induced by cell culture in human mesenchymal stem cells in GMP condition.
- Trial name
- MESSAGE (NCT00836732)
- Testing
- harvest of a small bone marrow sample
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Nantes University Hospital
Spinal Cord Injury
Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries
The purpose of this study is to analyze the potential clinical efficacy of intrathecal administration, in the subarachnoid space, of in vitro expanded autologous adult bone marrow mesenchymal stem cells in the treatment of…
- Trial name
- NCT02570932
- Testing
- Autologous Mesenchymal Bone Marrow Cell
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Puerta de Hierro University Hospital
Graft-versus-host-disease
Treatment of Steroid Resistant GVHD by Infusion MSC
For numerous malignant diseases allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy. One of the major complications is the occurrence of acute graft-versus-host-disease (aGVHD).
- Trial name
- MSCforGVHD (NCT00827398)
- Testing
- MSC (hPPL)
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- N.M. Wulffraat
COVID-19
Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia
The disease caused by the new coronavirus, SARS-CoV-2, called COVID-19, it has considered a worldwide pandemia by the WHO. Suddently, it produces a lot of patients severe ill, in a little geographic area, that could surpase the…
- Trial name
- CELMA (NCT04429763)
- Testing
- Umbilical cord derived mesenchymal stem cells
- Volunteers
- 30 people
- Sponsor
- Trustem
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease…
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT03533816
- Testing
- EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion)
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Kansas Medical Center
Graft Versus Host Disease, Lymphoma
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00006747
- Testing
- carmustine, melphalan, etoposide
- Where
- 48 sites in United States
- Volunteers
- 4 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Diabetic Foot Ulcer, Mesenchymal Stromal Cells
Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients.
The STEMFOOT Pilot Study is a single center randomized open phase I clinical intervention pilot trial with the aim of investigating the treatment effect of an allogenic adipose-derived mesenchymal stromal cell product (C2C_ASC)…
- Trial name
- STEMFOOT (NCT05595681)
- Testing
- Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Cell to Cure ApS
Children Cancer, Solid Tumor
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children
This is a prospective Phase II, monocentre study.
- Trial name
- MEP1 (NCT01225419)
- Testing
- Plerixafor, mozobil
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Myelomonocytic Leukemia (CMML), Immune Reconstitution
The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment.
- Trial name
- NCT07113730
- Testing
- immune reconstitution
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Core Binding Factor Alpha Subunits, Hematologic Neoplasms
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Background: Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with.
- Conditions
- Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
- Trial name
- NCT07524530
- Testing
- Cyclophosphamide, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Limb Ischemia, Diabetic Foot
Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia
Phase II national, multicenter, double-blind, randomized, placebo-controlled, phase-3 clinical trial of 3 parallel groups.
- Trial name
- NCT04466007
- Testing
- High dose allogeneic mesenchymal stromal cells, Low dose allogeneic mesenchymal stromal cells
- Where
- 10 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz